VCIM
HRTX icon

Velan Capital Investment Management’s Heron Therapeutics HRTX Stock Holding History

Velan Capital Investment Management’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.74M Hold
8,753,290
– – 2.28% 14
2026
Q1 		$7M Hold
8,753,290
– – 4.39% 8
2025
Q4 		$11.4M Hold
8,753,290
– – 6.6% 4
2025
Q3 		$11M Buy
8,753,290
+1,766,546
+25% +$2.8M 10.36% 1
2025
Q2 		$14.5M Hold
6,986,744
– – 14.29% 1
2025
Q1 		$15.4M Hold
6,986,744
– – 15.81% 1
2024
Q4 		$10.7M Hold
6,986,744
– – 9.22% 3
2024
Q3 		$13.9M Hold
6,986,744
– – 13% 4
2024
Q2 		$24.5M Hold
6,986,744
– – 14.01% 3
2024
Q1 		$19.4M Hold
6,986,744
– – 8.79% 5
2023
Q4 		$11.9M Hold
6,986,744
– – 6.93% 3
2023
Q3 		$7.2M Buy
6,986,744
+2,486,744
+55% +$3.54M 5.8% 4
2023
Q2 		$5.22M Hold
4,500,000
– – 4.85% 6
2023
Q1 		$6.79M Buy
4,500,000
+2,000,000
+80% +$5.01M 5.79% 6
2022
Q4 		$6.25M Buy
+2,500,000
New +$8.05M 5.52% 8

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
CC
Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Velan Capital Investment Management's HRTX Position: Q2 2026 in Review

Velan Capital Investment Management held its Heron Therapeutics (HRTX) position steady in Q2 2026 at 8,753,290 shares worth $3.74M. The position accounts for 2.28% of the portfolio, ranked #14.

Velan Capital Investment Management first reported a position in HRTX in Q4 2022 and has held it in 15 quarters since. The position peaked at $24.5M in Q2 2024. 163 funds tracked by Wall St. Rank hold HRTX as of Q2 2026.

  • Velan Capital Investment Management held 8,753,290 shares of Heron Therapeutics worth $3.74M as of Q2 2026.
  • Velan Capital Investment Management left its Heron Therapeutics share count unchanged in Q2 2026.
  • Heron Therapeutics made up 2.28% of Velan Capital Investment Management's portfolio in Q2 2026, its #14 holding.
  • Velan Capital Investment Management first reported a position in Heron Therapeutics in Q4 2022 and has held it in 15 quarters since.
  • Velan Capital Investment Management's Heron Therapeutics position peaked at $24.5M in Q2 2024.
  • 163 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2026.

Based on Velan Capital Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.